Shorter Treatment Time For Chagas Could Blunt Kissing Bug Disease
Chagas is in the spotlight with Novartis, Bayer and DNDi running different trials designed to tackle the neglected tropical parasitic disease.
You may also be interested in...
The latest US FDA approvals and actions from the Pink Sheet’s US FDA Performance Tracker.
The Boston-based biotech is weighing up its options as the fall-out from its failed IPF candidate casts a shadow over Galecto’s future.
Getting on the best reimbursement pathway in the US will be vital for the UK company as it moves closer to approval and taking on the established players in the chronic obstructive pulmonary disease arena.